TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05574374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: Potassium-competitive acid blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: Potassium-competitive acid blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: Potassium-competitive acid blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC202202
Description: Clopidogrel Bisulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC202202
Description: Clopidogrel Bisulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC202202
Description: Clopidogrel Bisulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC202203
Description: Proton pump inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC202203
Description: Proton pump inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC202203
Description: Proton pump inhibitor
Study: NCT06500871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Potassium
Description: NSAID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Potassium
Description: NSAID
Study: NCT05979818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol hydrochloride
Description: 10 mg, PO, BID, for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent.
Study: NCT06058689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide 4 MG Oral Capsule
Description: A single dose of 4 mg Pomalidomide per os, capsule, 4 mg, per period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide 4 MG Oral Capsule
Description: A single dose of 4 mg Pomalidomide per os, capsule, 4 mg, per period
Study: NCT04648878

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy only
Description: 18 visits of physical therapy only, three times a week for approximately 6 weeks
Study: NCT05830916

Intervention type: DIAGNOSTIC_TEST
Intervention: Antiphospholipid antibodies
Description: Antiphospholipid (aPL) antibodies are a heterogeneous group of autoantibodies with high affinity for phospholipids such lupus anticoagulant (LA), β2glycoprotien І (β2GPІ), and anticardiolipin (anti-CL). They interfere with physiological mechanisms of coagulation and fibrinolysis, leading the haemostatic balance towards coagulation. Moreover, it seems to affect the physiological function of various cells such as platelets and endothelial cells

Intervention type: DIAGNOSTIC_TEST
Intervention: Antiphospholipid antibodies
Description: Antiphospholipid (aPL) antibodies are a heterogeneous group of autoantibodies with high affinity for phospholipids such lupus anticoagulant (LA), β2glycoprotien І (β2GPІ), and anticardiolipin (anti-CL). They interfere with physiological mechanisms of coagulation and fibrinolysis, leading the haemostatic balance towards coagulation. Moreover, it seems to affect the physiological function of various cells such as platelets and endothelial cells
Study: NCT06065007

Intervention type: OTHER
Intervention: No intervention
Description: This is a cross-sectional observational study, no intervention will be implemented or exposure studied. Data for outcomes of interest will be collected via questionnaires
Study: NCT05202236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemigatinib
Description: The patients will receive 13.5 mg (1 pill/time) of pemigatinib once a day (QD) orally following a 2-week administration/1-week interruption regimen, with 21 days as a cycle. They should take pemigatinib at regular times of the day to avoid the effects of inconsistent timing on plasma concentrations.
Study: NCT06237842

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test: EEG headband+Ring oximeter (RO)+Actigraphy (ACT)
Description: Combination of ACT+RO+EEG. This is not an intervention, but rather a combination of devices to be tested regarding its diagnostic validity.

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test: EEG headband+Ring oximeter (RO)+Actigraphy (ACT)
Description: Combination of ACT+RO+EEG. This is not an intervention, but rather a combination of devices to be tested regarding its diagnostic validity.
Study: NCT05174052

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10Mg Tab
Description: Subjects will take 1 blinded tablet of study drug (dapagliflozin 10 mg) dosed once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take 1 blinded capsule of placebo drug dosed once daily
Study: NCT06135597

Intervention type: OTHER
Intervention: This is a blood test without regarding to intervention nor diagnostic tests
Description: This is a blood test without regarding to intervention nor diagnostic tests

Intervention type: OTHER
Intervention: This is a blood test without regarding to intervention nor diagnostic tests
Description: This is a blood test without regarding to intervention nor diagnostic tests

Intervention type: OTHER
Intervention: This is a blood test without regarding to intervention nor diagnostic tests
Description: This is a blood test without regarding to intervention nor diagnostic tests
Study: NCT05433298

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell
Description: Administration of advanced cell product

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ringer's lactate, albumin and heparin solution
Study: NCT06410781

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radial Extracorporeal Shockwave
Description: Treatment procedure will be initiated by palpation to locate the painful area around the lateral femoral condyle and the lateral side of the thigh. The therapist uses the principle of clinical focusing where the patient guides the therapist to the most painful area. The area will be treated in a circumferential pattern, starting at the point of maximum pain. At each of the session a total of 4600 pulses will be applied. RESWT will start with 500 pulses at (2 Bar) with the frequency of 15 Hz to the lateral femoral condyle to adjust to treatment.An additional 2000 pulses will be applied at (2- 4 Bar), 15 Hz, depending on pain tolerance. in addition,stretching exercise, manual therapy, and ultrasound on the iliotibial band.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional therapy
Description: the patients will receive traditional therapy in the form of stretching exercise, manual therapy and ultrasound on iliotibial band.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional therapy
Description: the patients will receive traditional therapy in the form of stretching exercise, manual therapy and ultrasound on iliotibial band.
Study: NCT05491005

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Total diet replacement
Description: Total diet replacement (850 kcal/day) for 3 months followed by weight maintenance for 21 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Total diet replacement
Description: Total diet replacement (850 kcal/day) for 3 months followed by weight maintenance for 21 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eHealth
Description: All follow-up through an eHealth application and video meetings.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-face
Description: All follow-up through face-to-face meetings.
Study: NCT05979818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: intravenous infusion (IV), 200 mg, Day1, Q3W, for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Platinum-based chemotherapy:~For non-squamous cell carcinoma options: carboplatin/cisplatin + pemetrexed; For squamous cell carcinoma: carboplatin/cisplatin + paclitaxel/gemcitabine. Carboplatin: IV, AUC 5, Day1, Q3W; Cisplatin: IV, 75 mg/m2, Day1-3, Q3W; Pemetrexed: IV, 500 mg/m2, Day1, Q3W; Paclitaxel: IV, 175 mg/m², Day1, Q3W; Albumin-bound paclitaxel: IV, 100 mg/m², Day1, 8, 15; or 260 mg/m2, Q3W; Gemcitabine: IV, 1000mg/m2, Day1, 8, Q3W; After 4-6 cycles of sintilimab and platinum-based chemotherapy, the patients of non-squamous cell carcinoma will be received with sintilimab and pemetrexed for maintenance therapy, for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent.
Study: NCT05616455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propionibacterium Acnes
Description: Application of the gel every 12 hours for 40 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glyceryl trinitrate
Description: Application of the gel every 12 hours for 40 days
Study: NCT05447416

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen Therapy - HBOT
Description: Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Hypoxic Training - IHT
Description: Each session lasts 60 minutes of 15.2% oxygen at 1.0 ATA. Subjects will be training according to individualized training protocol.
Study: NCT04112199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIV201 continuous infusion
Description: BIV201 continuous infusion with terlipressin for a total of two 28 day cycles. Initiate treatment at 3 mg per 24 hour period and titrate stepwise up to a maximum of 8 mg per 24 hour period based on tolerability and response.
Study: NCT05953987

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic combined with diaphragmatic breathing exercise (EXDB)
Description: The participant underwent diaphragmatic breathing exercises which were performed in a supine position, gradually in-creasing the weight by 2.5 kg in weeks 1-4 and further increasing to 5 kg in weeks 5-8. After completing the prescribed breathing exercises and taking a 60-second rest, participants proceeded to perform aerobic exercises, either by running on a treadmill or on a regular floor surface. Each training session began with a 5-minute warm-up comprising stretching exercises. In weeks 1-4, moderate intensity was maintained, targeting 40-50% of the heart rate reserve (HRR) for a duration of 60 minutes. From weeks 5-8, the intensity increased to the range of 51-60% of the heart rate reserve, and a 5-minute cool down was added

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise (EX)
Description: The participant underwent aerobic exercises, either by running on a treadmill or on a regular floor surface. Each training session began with a 5-minute warm-up comprising stretching exercises. In weeks 1-4, moderate intensity was maintained, targeting 40-50% of the heart rate reserve (HRR) for a duration of 60 minutes. From weeks 5-8, the intensity increased to the range of 51-60% of the heart rate reserve, and a 5-minute cool down was added.

Intervention type: OTHER
Group type: OTHER
Intervention: sedentary control (CON)
Description: The participant did not engage in the aerobic exercise training protocol or receive any form of supplementation during the study trial.
Study: NCT05759806

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nephronyx system (Perfuser)
Description: Temporary deployment of the Nephronyx system (Perfuser)
Study: NCT04399564

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: temporary hemodialysis catheters
Description: Vascular access using temporary vs.long-term hemodialysis catheters

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: long-term hemodialysis catheters
Description: long-term hemodialysis catheters
Study: NCT05791318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VYD222
Description: Monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VYD222
Description: Monoclonal antibody
Study: NCT06484751

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SelfBack
Description: The SelfBack app is a promising decision support system (DSS) App used globally to support and reinforce desired self-management behavior for LBP. Selfback's program goal is to improve the self-management of nonspecific LBP to reduce pain-related disability.
Study: NCT05010694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GH35 Tablet
Description: GH35 for oral administration at doses of Dose A, Dose B, Dose C, Dose D, Dose E and Dose F.
Study: NCT06390553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Task-Oriented Virtual Reality Application with Crowd Simulation
Description: Patients will be treated 4 days a week for 8 weeks in accordance with their assigned group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Parkinson Rehabilitation
Description: Patients will be treated 4 days a week for 8 weeks in accordance with their assigned group.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Parkinson Rehabilitation
Description: Patients will be treated 4 days a week for 8 weeks in accordance with their assigned group.
Study: NCT05879640

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sleep education
Description: Participants receive a handout about age appropriate sleep goals and tips for improving sleep. The handout also contains links to educational videos about sleep hygiene and the importance of sleep to healing after illness. The handout is reviewed with a clinician at bedside prior to hospital discharge.
Study: NCT05992233

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual wavelength low level laser
Description: Application of double wavelength low level laser to the related area after tooth extraction.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Only red light applied.
Study: NCT06187181

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant overdenture
Description: . Videofluoroscopy swallowing evaluation was done using 10 ml of thin liquid bolus at three different oral conditions: Without dentures (WOD), with the conventional complete denture (CDs) and with mandibular implant retained overdenture (IODs).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant overdenture
Description: . Videofluoroscopy swallowing evaluation was done using 10 ml of thin liquid bolus at three different oral conditions: Without dentures (WOD), with the conventional complete denture (CDs) and with mandibular implant retained overdenture (IODs).

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: videofluroscopy
Description: videofluroscopy evaluation of swallowing function

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: videofluroscopy
Description: videofluroscopy evaluation of swallowing function

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: videofluroscopy
Description: videofluroscopy evaluation of swallowing function
Study: NCT06336044

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Karisma
Description: Intradermal injection
Study: NCT04939103

Intervention type: DEVICE
Intervention: TRUS-FNA
Description: Transrectal Ultrasound Guided Fine Needle Aspiration for rectal tumor
Study: NCT05799157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VDMN-21 Patch Low Dose
Description: Microneedle patch containing 125 mcg of active drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VDMN-21 Patch High Dose
Description: Microneedle patch containing 250 mcg of active drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Patch
Description: Placebo microneedle patch containing no active drug (i.e., placebo)
Study: NCT06319274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost
Description: Continuously infusion for 72 hours at 3 ml/hours. Treatment dose 1 ng/kg/min

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Description: Continuously infusion for 72 hours at 3 ml/hours
Study: NCT05791318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VYD222
Description: Monoclonal antibody

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo
Study: NCT04964921

Intervention type: OTHER
Intervention: Device: ANSiScope Plus
Description: Heart rate variability measurement and vital signs monitoring will be performed on all subjects.
Study: NCT06426927

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colorectal Cancer Educational Videos in Spanish
Description: Enrolled participants will watch three educational videos on Colorectal Cancer (CRC) in Spanish. Knowledge on CRC symptoms, risk factors, facts, screening and treatment will be assessed before and immediately after the educational video and at 30 +/- 7 days. In addition, the association between increase in CRC knowledge and willingness to participate in Cancer Clinical Trials (CCT) will be explored.
Study: NCT05980299

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized Positive Psychosocial Interaction
Description: The intervention involves a brief positive interaction around a preferred activity or personal care routine.
Study: NCT05144295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone Pill
Description: Oral pills for constipation (Lubiprostone) will be given in a dose range from 24 mcg once daily to 24 mcg twice daily according to the participant weight.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose Oral Liquid Product
Description: Lactulose  Lactulose, or Duphalac syrup at a dose of 1 ml/kg once or twice daily (maximum 60 mL/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisacodyl 5 MG
Description: Bisacodyl tablet (5 mg/tablet) in a dose of 2 tab/day for \< 12 years or 3 tab/day for \> 12 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Picosulfate
Description: Sodium Picosulfate 0.75% drops in a daily dose of 2.5-20 mg/day
Study: NCT05967234

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth solution
Description: Telehealth solution offered for breastfeeding education.
Study: NCT04825093

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D supplementation in pregnant women
Description: Intervention group will be administered 1,000 UI of vitamin D and a control group will be administered 400 UI of vitamin D. Participants will take the supplementation from the enrollment to delivery.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation in pregnant women
Description: Intervention group will be administered 1,000 UI of vitamin D and a control group will be administered 400 UI of vitamin D. Participants will take the supplementation from the enrollment to delivery.
Study: NCT04686734

Intervention type: OTHER
Intervention: No active intervention (observational only)
Description: No active intervention (observational only)

Intervention type: OTHER
Intervention: No active intervention (observational only)
Description: No active intervention (observational only)
Study: NCT05642130

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exersice program (Muscle energy technique)
Description: Post isometric relaxation for upper trapezius and sternocleidomastoid muscles. the therapist moved the subject's head into the position that put each muscle in stretch, once resistance/ barrier was felt, that position was held and subjects were asked to isometrically contract the target muscle with 20% of maximal contraction for 5 sec against mild resistance from the therapist, relax for 5 sec followed by passive stretch until reaching a new barrier for 30 sec, 3 repetitions for each muscle, 3sessions /week over a period of 4 weeks, In addition to the program designed for control group

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: exersice program (stretching and strengthening exercises ) In addition to postural advices
Description: static stretching exercise for upper trapezius and sternocleidomastoid . Repetitions: 3times/day, 3days/week over a period of 4 weeks, in addition to strengthening exercises of deep cervical flexors and scapular retractor muscles, 3sets of 12 repetitions with 6 sec hold. In addition to postural advices

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exersice program (stretching and strengthening exercises ) In addition to postural advices
Description: static stretching exercise for upper trapezius and sternocleidomastoid . Repetitions: 3times/day, 3days/week over a period of 4 weeks, in addition to strengthening exercises of deep cervical flexors and scapular retractor muscles, 3sets of 12 repetitions with 6 sec hold. In addition to postural advices
Study: NCT04572854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan
Description: Complement (C3) Inhibitor
Study: NCT06571656

Intervention type: OTHER
Group type: OTHER
Intervention: FID123359 test formulation
Description: Investigational product

Intervention type: OTHER
Group type: OTHER
Intervention: FID123359 test formulation
Description: Investigational product

Intervention type: OTHER
Group type: OTHER
Intervention: FID123359 test formulation
Description: Investigational product

Intervention type: OTHER
Group type: OTHER
Intervention: FID123359 test formulation
Description: Investigational product

Intervention type: OTHER
Group type: OTHER
Intervention: FID123360 test formulation
Description: Investigational product

Intervention type: OTHER
Group type: OTHER
Intervention: FID123360 test formulation
Description: Investigational product

Intervention type: OTHER
Group type: OTHER
Intervention: FID123360 test formulation
Description: Investigational product

Intervention type: OTHER
Group type: OTHER
Intervention: FID123360 test formulation
Description: Investigational product

Intervention type: OTHER
Group type: OTHER
Intervention: FID123361 test formulation
Description: Investigational product

Intervention type: OTHER
Group type: OTHER
Intervention: FID123361 test formulation
Description: Investigational product

Intervention type: OTHER
Group type: OTHER
Intervention: FID123361 test formulation
Description: Investigational product

Intervention type: OTHER
Group type: OTHER
Intervention: FID123361 test formulation
Description: Investigational product

Intervention type: OTHER
Group type: OTHER
Intervention: FID121843 ocular lubricant
Description: Commercially available, preservative-free eye drops

Intervention type: OTHER
Group type: OTHER
Intervention: FID121843 ocular lubricant
Description: Commercially available, preservative-free eye drops

Intervention type: OTHER
Group type: OTHER
Intervention: FID121843 ocular lubricant
Description: Commercially available, preservative-free eye drops

Intervention type: OTHER
Group type: OTHER
Intervention: FID121843 ocular lubricant
Description: Commercially available, preservative-free eye drops